CASI Pharmaceuticals, Inc. has acquired a U.S. FDA-approved abbreviated new drug application (ANDA) from Laurus Labs Ltd. The drug, tenofovir disoproxil fumarate (TDF), is indicated for the treatment of hepatitis B virus (HBV). As part of the transaction, CASI will make certain upfront and milestone payments.  There are more than 90 million chronic carriers of hepatitis B in China which accounts for roughly one-third of all HBV chronic carriers in the world, with TDF currently as the first line ...